CRPC w/ Bone Metastases - Results from #220

REVIEW UroToday

Clinical Outcomes and Survival Following Treatment of Metastatic Castrate-Refractory Prostate Cancer With Docetaxel Alone or With Strontium-89, Zoledronic Acid, or Both: The TRAPEZE Randomized Clinical Trial February 22, 2016

Skeletal Tumor Burden on Baseline 18F-Fluoride PET/CT Predicts Bone Marrow Failure After 223Ra Therapy February 21, 2016

Mechanistic Support for Combined MET and AR Blockade in Castration-Resistant Prostate Cancer February 20, 2016

Radiotherapy Combined With Androgen Deprivation for Bone Oligometastases After Primary Curative Radiotherapy for Prostate Cancer: A Retrospective Study February 15, 2016

Targeting Met and VEGFR Axis in Metastatic Castration-Resistant Prostate Cancer: 'Game Over'? February 9, 2016

A combination of sorafenib and nilotinib reduces the growth of castrate-resistant prostate cancer January 27, 2016

A randomized phase II clinical trial of personalized peptide vaccination with metronomic low-dose cyclophosphamide in patients with metastatic castration-resistant prostate cancer January 6, 2016

Molecular Mechanisms of Bone Metastasis December 31, 2015

Whole-Body and Microenvironmental Localization of Radium-223 in Naïve and Mouse Models of Prostate Cancer Metastasis. December 20, 2015

A case report of image-based dosimetry of bone metastases with Alpharadin ((223)Ra-dichloride) therapy: inter-fraction variability of absorbed dose and follow-up December 17, 2015

Continuous use of enzalutamide in a patient who developed enzalutamide-induced thrombocytopenia December 17, 2015

Failure-Free Survival and Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer: Data From Patients in the Control Arm of the STAMPEDE Trial December 17, 2015

Health Economics and Radium-223 (Xofigo®) in the Treatment of Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Case History and a Systematic Review of the Literature. November 24, 2015

[Vertebral metastases of urogenital carcinomas : Diagnosis and conservative therapy] October 20, 2015

Comparative efficacy, tolerability, and survival outcomes of various radiopharmaceuticals in castration-resistant prostate cancer with bone metastasis: a meta-analysis of randomized controlled trials October 19, 2015

Effects of concomitant use of abiraterone and/or enzalutamide with radium-223 on safety and overall survival in metastatic castration-resistant prostate cancer (mCRPC) patients treated in an international early access program (EAP) October 14, 2015

Management of bone metastases in prostate cancer: a review September 22, 2015

Stochastic simulation of radium-223 dichloride therapy at the sub-cellular level September 9, 2015

Multimodal Partial Volume Correction - Application to 18F-Fluoride PET/CT bone metastases studies September 4, 2015

Bayer Supports Prostate Cancer Awareness Efforts in Communities Nationwide throughout September September 3, 2015

Page 12 of 15